WHAT ARE BIOSIMILARS?

organisms, no two batches are identical² Biosimilars are biological medicines (biologics). Biologics are large, complex molecules from natural sources human, animal or microorganism¹



Biosimilars are so-called because they are highly similar to already marketed biologics, known as reference products³

HOW ARE THEY REGULATED?



In Europe all biosimilars are approved by the **European Medicines** Agency (EMA)4

Every part of the drug development process is assessed prior to approval to demonstrate that the biosimilar is equivalent to the reference product5



The first biosimilar was approved in 2006 and there are now 20 approved biosimilars in Europe^{3,6}







There have been no safety concerns identified for approved and marketed biosimilars to date (2013)7



WHY ARE THEY NEEDED?



Biosimilars are typically made available at a lower cost than the reference product after the patents and **Supplementary Protection Certificates** protecting that product have expired7

One of the most significant new developments is biosimilar monoclonal antibodies which are projected to save European healthcare systems between

Because they are derived from living

.8bn and €20.4l

between 2007 and 2020⁸





The cost savings provided by biosimilars can help improve patient access to safe and effective biological medicines⁷

- 1. What is a biological product? FDA http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm Last accessed 13.10.14
- Weise M, et al. Biosimilars: What clinicians should know. Blood 2012; 120(26):5111-5117
 Biological and Biosimilar Medicines Fact Sheet 2: An Information and Advocacy Toolkit for Patients' Organizations,
 IAPO http://iapo.org.uk/sites/default/filesfiles/IAPO%20Factsheet_2.pdf Last accessed 7.10.14
 FAQs About Biosimilar Medicines. European Generics Association http://www.egagenerics.com/index.php/biosimilar-medicines/faq-on-biosimilars Last accessed 6.10.14
 Quick Guide on Biological and Biosimilar Medicines. IAPO November 2013 http://iapo.org.uk/sites/default/filesfiles/IAPO%20Guide.pdf Last accessed 7.10.14
 Placimilars approach in Europe Conspicts and Riscimilars Lisitation.

- 6. Biosimilars approved in Europe, Generics and Biosimilars Initiative http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe Last accessed 13.10.14
- 7. What you need to know about biosimilar medicinal products. Consensus document, European Commission 2013 http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf Last accessed 13.10.14
- The Future of Biosimilar mAbs in Europe 2013. http://gabionline.net/Biosimilars/Research/The-future-of-biosimilar-mAbs-in-Europe Last accessed 15.11.14

